丹香冠心注射液联合替格瑞洛治疗急性心肌梗死的临床研究  

Clinical study on Danxiang Guanxin Injection combined with ticagrelor tablets in treatment of acute myocardial infarction

作　　者：刘伯欣 郝明辉[2] 陈文明[2] LIU Boxin;HAO Minghui;CHEN Wenming(Department of Emergency,Beijing Luhe Hospital,Capital Medical University,Beijing 101100,China;Department of Cardiology,Beijing Luhe Hospital,Capital Medical University,Beijing 101100,China)

机构地区：[1]首都医科大学附属北京潞河医院急诊科,北京101100 [2]首都医科大学附属北京潞河医院心内科,北京101100

出　　处：《现代药物与临床》2024年第3期637-641,共5页Drugs & Clinic

基　　金：北京市通州区支持科技创新专项项目(KJ2018CX009-40)。

摘　　要：目的探讨丹香冠心注射液联合替格瑞洛片治疗急性心肌梗死的临床疗效。方法选取2019年2月—2023年5月在首都医科大学附属北京潞河医院接受治疗的急性心肌梗死患者95例。依据用药情况分为对照组(47例)和治疗组(48例)。对照组口服替格瑞洛片,90 mg/次,2次/d。治疗组在对照组的基础上静脉滴注丹香冠心注射液,20 mL加入5%葡萄糖注射液250 mL,1次/d。两组患者治疗4周。观察两组患者临床疗效,比较治疗前后两组患者左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、心脏指数(CI)、心输出量(CO)和E峰流速/A峰流速(E/A)、左心室后壁厚度(LVPWT)、左室心肌重量指数(LVMI)以及舒张期室间隔厚度(IVST)、髓过氧化物酶(MPO)、血清淀粉样蛋白A1(SAA1)和可溶性生长刺激表达基因2蛋白(sST2)水平。结果治疗后,治疗组总有效率为89.58%,明显高于对照组(70.21%,P<0.05)。治疗后,两组患者LVESD、LVPWT、IVST、MPO、SAA1和sST2指标水平明显降低,而LVEF、CI、CO、E/A和LVMI指标显著升高(P<0.05),且治疗组患者这些指标水平明显好于对照组(P<0.05)。结论丹香冠心注射液联合替格瑞洛片可显著提高急性心肌梗死治疗的临床有效率,改善心肌功能和逆转心室重构,降低心肌损伤和炎症反应。Objective To investigate the clinical effect of Danxiang Guanxin Injection combined with Ticagrelor Tablets in treatment of acute myocardial infarction.Methods Patients(95 cases)with acute myocardial infarction in Beijing Luhe Hospital,Capital Medical University from February 2019 to May 2023 were divided into control(47 cases)and treatment(48 cases)group according to the different treatments.Patients in the control group were po administered with Ticagrelor Tablets,90 mg/time,twice daily.Patients in the treatment group were iv administered with Danxiang Guanxin Injection on the basis of the control group,20 mL added into 5%glucose injection 250 mL,once daily.Patients in two groups were treated for 4 weeks.After treatment,the clinical evaluations were evaluated,the levels of LVESD,LVEF,CI,CO,E/A,LVPWT,IVST,LVM,MPO,SAA1 and sST2 in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group was 89.58%,which was significantly higher than that of the control group(70.21%,P<0.05).After treatment,the levels of LVESD,LVPWT,IVST,MPO,SAA1,and sST2 were significantly decreased,while LVEF,CI,CO,E/A,and LVMI were significantly increased in two groups(P<0.05),and the level of these indexes in the treatment group was significantly better than that in the control group(P<0.05).Conclusion Danxiang Guanxin Injection combined with Ticagrelor Tablets can significantly improve the clinical effective rate of acute myocardial infarction,improve myocardial function and reverse ventricular remodeling,and reduce myocardial injury and inflammation.

关 键 词：丹香冠心注射液 替格瑞洛片 急性心肌梗死 心肌功能 心室重构 髓过氧化物酶 血清淀粉样蛋白A1 

分 类 号：R972[医药卫生—药品]